JP2024547112A5 - - Google Patents
Info
- Publication number
- JP2024547112A5 JP2024547112A5 JP2024537982A JP2024537982A JP2024547112A5 JP 2024547112 A5 JP2024547112 A5 JP 2024547112A5 JP 2024537982 A JP2024537982 A JP 2024537982A JP 2024537982 A JP2024537982 A JP 2024537982A JP 2024547112 A5 JP2024547112 A5 JP 2024547112A5
- Authority
- JP
- Japan
- Prior art keywords
- crystal
- methyl
- powder
- represented
- characteristic peaks
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111586541 | 2021-12-23 | ||
| CN202111586541.3 | 2021-12-23 | ||
| PCT/CN2022/141407 WO2023116879A1 (zh) | 2021-12-23 | 2022-12-23 | 一种glp-1受体激动剂的结晶形式及其制备方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024547112A JP2024547112A (ja) | 2024-12-26 |
| JP2024547112A5 true JP2024547112A5 (enExample) | 2026-05-08 |
Family
ID=86901327
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024537982A Pending JP2024547112A (ja) | 2021-12-23 | 2022-12-23 | Ｇｌｐ－１受容体作動薬の結晶形及びその調製方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250049778A1 (enExample) |
| EP (2) | EP4455140B1 (enExample) |
| JP (1) | JP2024547112A (enExample) |
| KR (1) | KR20240125004A (enExample) |
| CN (1) | CN118401518A (enExample) |
| AU (1) | AU2022422997A1 (enExample) |
| CA (1) | CA3241677A1 (enExample) |
| MX (1) | MX2024007907A (enExample) |
| TW (1) | TW202328115A (enExample) |
| WO (1) | WO2023116879A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2024340407A1 (en) | 2023-09-14 | 2026-04-23 | Ascletis Pharma (China) Co., Limited | Glp-1r agonist and therapeutic method thereof |
| WO2025109387A1 (en) | 2023-11-24 | 2025-05-30 | Ascletis Pharma (China) Co., Limited | Glp-1r agonist and therapeutic method thereof |
| WO2025189141A1 (en) | 2024-03-08 | 2025-09-12 | Annapurna Bio, Inc. | Methods for treating obesity and increasing weight loss |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10934279B2 (en) * | 2018-06-13 | 2021-03-02 | Pfizer Inc. | GLP-1 receptor agonists and uses thereof |
| JP2023528565A (ja) * | 2020-04-01 | 2023-07-05 | ハンジョウ ジョンメイ フアドン ファーマシューティカル シーオー．，エルティーディー． | Ｇｌｐ－１受容体アゴニストの結晶形ａおよびその調製法 |
| PL4157832T3 (pl) * | 2020-05-27 | 2024-12-16 | Qilu Regor Therapeutics Inc. | Sól i postacie krystaliczne agonistów GLP-1R oraz ich zastosowania |
| CN119930605A (zh) * | 2020-09-01 | 2025-05-06 | 江苏恒瑞医药股份有限公司 | 稠合咪唑类衍生物、其制备方法及其在医药上的应用 |
| WO2022228490A1 (zh) * | 2021-04-30 | 2022-11-03 | 上海翰森生物医药科技有限公司 | 多环类衍生物调节剂、其制备方法和应用 |
-
2022
- 2022-12-23 JP JP2024537982A patent/JP2024547112A/ja active Pending
- 2022-12-23 US US18/722,345 patent/US20250049778A1/en active Pending
- 2022-12-23 KR KR1020247024148A patent/KR20240125004A/ko active Pending
- 2022-12-23 MX MX2024007907A patent/MX2024007907A/es unknown
- 2022-12-23 AU AU2022422997A patent/AU2022422997A1/en active Pending
- 2022-12-23 CN CN202280084770.1A patent/CN118401518A/zh active Pending
- 2022-12-23 CA CA3241677A patent/CA3241677A1/en active Pending
- 2022-12-23 WO PCT/CN2022/141407 patent/WO2023116879A1/zh not_active Ceased
- 2022-12-23 EP EP22910190.2A patent/EP4455140B1/en active Active
- 2022-12-23 EP EP26159633.2A patent/EP4725484A2/en active Pending
- 2022-12-23 TW TW111149828A patent/TW202328115A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW201524507A (zh) | 雜環化合物及其用途 | |
| HU227625B1 (en) | Modifications of 2-amino-4-(4-fluorobenzylamino)-1-ethoxycarbonyl-aminobenzene and processes for preparing them | |
| JP2024547113A5 (enExample) | ||
| TWI333419B (en) | Crystalline sodium salt, process for the manufacture thereof and use thereof for the preparation of a medicament | |
| JPH04266824A (ja) | 医薬品 | |
| CN1275126A (zh) | 2－(3－氰基－4－异丁氧基苯基)－4－甲基－5－噻唑甲酸的多晶型体及其制备方法 | |
| JP2022540668A5 (enExample) | ||
| JP2002543075A (ja) | チアゾリジンジオン誘導体および抗糖尿病薬としてのその使用 | |
| TW202200594A (zh) | 一種glp-1受體激動劑的晶型a及其製備方法 | |
| JP2012072168A (ja) | エスシタロプラムの結晶質塩基、およびエスシタロプラム塩基を含む口腔内分散性錠剤 | |
| JP5654462B2 (ja) | 貧溶媒添加法による２−（３−シアノ−４−イソブチルオキシフェニル）−４−メチル−５−チアゾールカルボン酸の結晶多形体の製造方法 | |
| WO2009049495A1 (en) | Crystalline imidazol-5-carboxylic acid derivate | |
| JP2009161544A (ja) | チアゾリジンジオン誘導体および抗糖尿病薬としてのその使用 | |
| JP2002543076A (ja) | チアゾリジンジオン誘導体および抗糖尿病薬としてのその使用 | |
| JP2022540678A5 (enExample) | ||
| JP2023517729A5 (enExample) | ||
| EP1861389B1 (fr) | Sel besylate de la 7-(2-(4-(3-trifluoromethyl-phenyl)-1,2,3,6-tetrahydro-pyrid-1-yl)ethyl) isoquinoleine, sa preparation et son utilisation en therapeutique | |
| JP2012509930A (ja) | 新規な方法および純粋な多型 | |
| JP2002505254A (ja) | パロキセチン塩 | |
| JP2000344748A (ja) | ３−芳香族置換プロピオン酸またはアクリル酸化合物 | |
| JP2010540440A5 (enExample) | ||
| JP4177883B2 (ja) | 結晶性ピラゾール誘導体 | |
| CN106117104B (zh) | 一种维格列汀的制备方法 | |
| TWI336695B (en) | Stable polymorph of bifeprunox mesilate (7-[4-([1,1'-biphenyl]-3-ylmethyl)-1-piperazinyl]-2(3h)-benzoxazolone monomethanesulfonate) | |
| CN109651349B (zh) | 磺胺类化合物的新晶型以及制备方法和应用 |